Zonisamide for the treatment of epilepsy

Expert Review of Neurotherapeutics

Volumn 6, Issue 9, 2006, Pages 1283-1292

  Arzimanoglou, Alexis ^a,b   Rahbani, Abdallah ^a,c  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c Clinique Levant   (Lebanon)

Author keywords

Antiepileptic drugs; Epilepsy; Zonisamide

Indexed keywords

CARBAMAZEPINE; CIMETIDINE; DESIPRAMINE; ETHOSUXIMIDE; IMMUNOGLOBULIN A; LACTATE DEHYDROGENASE; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; SULFONAMIDE; UREA; VALPROIC ACID; VIGABATRIN; WARFARIN; ZONISAMIDE;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE; ANHIDROSIS; ANOREXIA; ANXIETY; APPETITE DISORDER; ATAXIA; ATONIC SEIZURE; CLINICAL TRIAL; CONFUSION; DEPRESSION; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG UTILIZATION; DURA MATER; EPILEPSY; FATIGUE; FECES INCONTINENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HYPERTHERMIA; IMMUNOGLOBULIN BLOOD LEVEL; INCIDENCE; INSOMNIA; IRRITABILITY; LACTATE DEHYDROGENASE BLOOD LEVEL; LENNOX GASTAUT SYNDROME; MAXIMUM ALLOWABLE CONCENTRATION; MEMORY DISORDER; MENTAL DISEASE; MICTURITION DISORDER; MONOTHERAPY; MUSCLE WEAKNESS; MYOCLONUS SEIZURE; NAUSEA AND VOMITING; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NONHUMAN; NYSTAGMUS; RASH; REVIEW; RHINITIS; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; TONIC CLONIC SEIZURE; UREA NITROGEN BLOOD LEVEL; VERTIGO; WEST SYNDROME;

ANTICONVULSANTS; CLINICAL TRIALS; EPILEPSY; HUMANS; ISOXAZOLES; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME;

EID: 33750087289     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.9.1283     Document Type: Review

References (28)

1. Arzimanoglou A, Guerrini R, Aicardi J. Aicardi's Epilepsy in Children (3rd Edition). Lippincott Williams and Wilkins, PA, USA (2004).
2. Antiepileptic Drugs (5th Edition). Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams and Wilkins, PA, USA (2002).
3. Shah J, Shellenberger K, Canafax DM. Zonisamide: chemistry, biotransformation and pharmacokinetics. In: Antiepileptic Drugs (5th Edition). Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams and Wilkins, PA, USA, 873-879 (2002).
4. MacDonald RL. Zonisamide: mechanisms of action. In: Antiepileptic Drugs (5th Edition). Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams and Wilkins, PA, USA, 867-872 (2002).
5. Mather GG, Shah J. Zonisamide: Drug interactions. In: Antiepileptic Drugs (5th Edition) Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams and Wilkins, Philadelphia, USA, 880-884 (2002).
6. Yagi K. Overview of Japanese experience: controlled and uncontrolled trials. Seizure 13(Suppl.), S11-S15 (2004).
7. Yamauchi T, Aikawa H. Efficacy of zonisamide: our experience. Seizure 13(Suppl. 1), S41-S49 (2004).
8. Ohtahara S: Zonisamide in the management of epilepsy - Japanese experience. Epilepsy Res. 68(Suppl. 2), S25-S33 (2006). • Open trials on new indications for zonisamide.
9. Suzuki Y: Zonisamide in West syndrome. Brain Dev. 23(7), 658-661 (2001).
10. Suzuki Y, Imai K, Toribe Y et al. Long-term response to zonisamide in patients with West syndrome. Neurology 58(10), 1556-1559 (2002).
11. Yanagakia S, Ogunia H, Yoshiia K et al. Zonisamide for West syndrome: a comparison of clinical responses among different titration rate. Brain Dev. 27, 286-290 (2005).
12. Linuma K, Haginoya K. Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey. Seizure 13(Suppl.), S34-S39 (2004).
13. Schmidt D, Jacob R, Loiseau P et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 15(1), 67-73 (1993).
14. Brodie M. Zonisamide clinical trials: European experience. Seizure 135, S66-S70 (2004).
15. Brodie M, Duncan R, Vespigniani H, Solyom A, Bitenskyy V, Lucas C. Dose dependent safety and efficacy of zonisamide: a randomized, double blind, placebo-controlled study in patients with refractory partial seizures Epilepsia 46(1), 31-41 (2005). •• Important controlled trials of zonisamide.
16. Sackellares JC, Ramsay RE, Wilder BJ, Browne TR 3rd, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 45(6), 610-617 (2004).
17. Faught E, Ayala R, Montouris GG, Leppik IE, Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 57, 1774-1779 (2001). •• Important controlled trials of zonisamide.
18. Santos CC, Brotherton T. Use of zonisamide in pediatric patients. Pediatr. Neurol. 33(1), 12-14 (2005).
19. Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Res. 64, 31-34 (2005).
20. Wilfong AA. Zonisamide monotherapy for epilepsy in children and young adults. Pediatr. Neurol. 32, 77-80 (2005).
21. Kothare SV, Kaleyias J, Mostofi N et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr. Neurol. 34(5), 351-354 (2006).
22. Kothare SV, Valencia I, Khurana DS, Hardison H, Melvin JJ, Legido A. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord. 6(4), 267-270 (2004). • Open trials on new indications for zonisamide.
23. Ohtahara S, Yamatogi Y. Safety of zonisamide therapy: prospective follow-up survey. Seizure 13(Suppl.), S50-S55 (2004).
24. Seino M, Ohkumo T, Miyasaka M et al. Efficacy evaluation of AD-810: results of a double blind comparison with carbamazepine. J. Clin. Exp. Med. 144, 275-291 (1988). [In Japanese]
25. Leppik IE. Practical prescribing and long-term efficacy and safety of zonisamide. Epilepsy Res. 68(Suppl 2), S17-S24 (2006).
26. Low PA, James S, Peschel T, Leong R, Rothstein A. Zonisamide and associated oligohidrosis and hyperthermia. Epilepsy Res. 62, 27-34 (2004).
27. Kondo T, Kaneko S, Amano Y et al. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 37, 1241-1244 (1996).
28. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst. Rev. 19(4), CD0014 (2005).